• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

12.82 +0.04 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
August 12, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
August 06, 2026
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 05, 2026
From Summit Therapeutics
Via Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst ↗
July 23, 2026
Via Chartmill
News headline image
Summit Therapeutics Q2 Earnings Call Highlights ↗
July 23, 2026
Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail... 
Via MarketBeat
Topics Earnings
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
June 30, 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
June 04, 2026
From Summit Therapeutics
Via Business Wire
News headline image
This Emerging Risk Is Unlike Anything the Biotech Industry Has Ever Experienced ↗
May 31, 2026
Biotech companies have always licensed programs, but never so many from one region in particular. 
Via The Motley Fool
News headline image
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
May 31, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
May 30, 2026
From Summit Therapeutics
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
May 23, 2026
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
May 23, 2026
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026
From USA News Group
Via GlobeNewswire
What's going on in today's session ↗
May 01, 2026
Via Chartmill
Which stocks are moving on Friday? ↗
May 01, 2026
Via Chartmill
News headline image
Summit Therapeutics Stock Dips After Q1 Financial Report ↗
May 01, 2026
Summit Therapeutics Inc (NASDAQ:SMMT) shares are plummeting after reporting its first‑quarter financial results. Here's what you should know. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
May 01, 2026
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
May 01, 2026
Via Chartmill
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
April 30, 2026
Via Chartmill
News headline image
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
April 30, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026
March 27, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
March 25, 2026
The next 10 months might be challenging for this biotech. 
Via The Motley Fool
News headline image
Summit Therapeutics to Present at Upcoming Investor Conferences
February 26, 2026
From Summit Therapeutics
Via Business Wire
News headline image
Summit (SMMT) Q4 2025 Earnings Call Transcript ↗
February 23, 2026
Summit (SMMT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap